KM Research Hub
← 返回结果库查看论文详情PubMed ↗
READ-ONLY DIGITIZATION RESULT

Absolute Eczema Area and Severity Index Responses with Lebrikizumab in Patients with Moderate-to-severe Atopic Dermatitis: A Secondary Analysis of Two Phase 3 Trials.

Acta Derm Venereol · 2026-May-21 · PMID 42163822

Panel EASI_1质量警告待 EXE 对齐验证

EASI ≤1 response rate

Fig. 4.. Response rates at week 52 among week-16 EASI 75 LEB responders. Each chart compares EASI response rates among week-16 EASI 75 LEB responders who were re-randomized into two LEB treatment arms and one LEB withdrawal arm. Data from weeks 16–52 are provided. Week-16 EASI 75 LEB responders who received systemic rescue medication, discontinued treatment due to lack of efficacy or transferred to the escape arm had values set to their baseline value after that time point through week 52. Those who received topical rescue medication or discontinued treatment for other reasons had values set to “missing” after that time point through week 52. Multiple imputation was used to handle missing data. Abbreviations: EASI, eczema area and severity index; LEB, lebrikizumab; Q2W, every 2 weeks; Q4W, every 4 weeks.

算法:legacy-0.5.0引擎:enhanced-linux
质量评分0.65
质量通过否
预期曲线3
实际曲线1
X 范围-
Y 范围-

曲线数据

网页最多预览 200 行,完整数据请下载 CSV 或 JSON。

当前面板没有可预览的 `curves_mapped.csv` 数据。
历史版本(1)

重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。

版本状态验证曲线时间
legacy-0.5.0quality_warning待验证12026-07-23T17:53:26+00:00